Dr. Gert A. Caspritz

• 
  www.epicept.com/About_Us/Leadership/Board_of_Directors/ - [Cached Version]
  Published on: 5/29/2008    Last Visited: 5/29/2008  

  Gert Caspritz, Ph.D.

• 
  www.sec.gov/Archives/edgar/data/1208261/0000909518-06-0 - [Cached Version]
  Published on: 5/26/2006    Last Visited: 6/1/2006  

  0001326639 Caspritz Gert C/O EPICEPT CORPORTION 270 SYLVAN AVENUE ENGLEWOOD CLIFFS, NJ 07632 1 0 0 0

• 
  www.clavispharma.com/Company/Board+of+Directors - [Cached Version]
  Published on: 11/3/2009    Last Visited: 11/3/2009  

  Gert Caspritz Board Member

• 
  www.sec.gov/Archives/edgar/data/1326639/0001209191-08-0 - [Cached Version]
  Published on: 10/8/2008    Last Visited: 10/9/2008  

  0001326639 Caspritz Gert C/O EPICEPT CORPORATION 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 0 0 0

• 
  www.sec.gov/Archives/edgar/data/1208261/0000909518-06-0 - [Cached Version]
  Published on: 1/9/2006    Last Visited: 1/10/2006  

  0001326639 Caspritz Gert C/O EPICEPT CORPORATION 270 SYLVAN AVENUE ENGLEWOOD CLIFFS NJ 07632 1 0 0 0

• 
  www.coleypharma.com/coley/board_bio_caspritz - [Cached Version]
  Published on: 5/13/2006    Last Visited: 5/13/2006  

  Gert Caspritz, Ph.D.General Partner, TVM Capital
  ...
  Gert Caspritz, Ph.D.General Partner, TVM Capital
  
  Dr. Caspritz has served as a director since October 1999.Dr. Caspritz is currently a General Partner at TVM Capital, an international biotechnology venture capital firm based in Germany.Prior to joining TVM Capital in June 1999, he was employed by Hoechst Marion Roussel (now sanofi-aventis), a pharmaceutical company, for over 15 years, most recently as Vice President of New Technologies Licensing.Dr. Caspritz serves on the board of directors of a number of privately held companies.Dr. Caspritz received his undergraduate degree in biology and his Ph.D. in biology from the University of Mainz, Germany.
  
  border=0Robert L. Bratzler Kenneth M. Bate Gert Caspritz

• 
  www.sec.gov/Archives/edgar/data/1326639/0001181431-05-0 - [Cached Version]
  Published on: 8/17/2005    Last Visited: 3/29/2006  

  0001326639 Caspritz Gert C/O COLEY PHARMACEUTICAL GROUP, INC. 93 WORCESTER STREET, SUITE 101 WELLESLEY MA 02481 1 0 0 0

• 
  www.clavispharma.com/page?id=1717&key=75017 - [Cached Version]
  Published on: 6/24/2009    Last Visited: 6/24/2009  

  Gert Caspritz Elected 2009 Clavis Pharma - Company - - Gert Caspritz
  
  Clavis Pharma logo
  ...
  Gert Caspritz
  
  Gert Caspritz joined NeoMed Management as senior investment professional and partner in September 2008.
  
  From 1999 to 2008 he was an Investment Manager and General Partner at TVM Capital's life science practice in Boston. Prior to that he worked for 18 years at Hoechst AG and its various affiliates (now known as Sanofi-Aventis) in Frankfurt, Germany; Kansas City, KS and Bridgewater, NJ.
  
  His most recent position was Vice President of New Technologies Licensing in the Global Business Development Group, where he also oversaw investments in various life science venture capital funds. During his tenure at Hoechst he also served two years as the Assistant to the Head of Worldwide Research with broad responsibilities for budget, personnel and investments.
  
  Gert Caspritz received a PhD in Biology from the Johannes Gutenberg University in Mainz, Germany in 1981. During his tenure at TVM Capital, Gert Caspritz has been a board member of several life science companies, most recently Enanta Pharmaceuticals, Transave and Transmolecular.
  
  Gert Caspritz is a citizen of Germany.

• 
  www.sec.gov/Archives/edgar/data/1319197/0001193125-06-0 - [Cached Version]
  Published on: 4/27/2006    Last Visited: 8/7/2008  

  Our Board of Directors currently consists of eight members, classified into three classes as follows: (1) Robert L. Bratzler, Ph.D. and Gert Caspritz, Ph.D. constitute a class with a term ending at the 2006 annual meeting; (2) James E. Thomas, Anthony B. Evnin, Ph.D. and Patrick Langlois, Ph.D. constitute a class with a term ending at the 2007 annual meeting; and (3) Kenneth M. Bate, Robert J. Hugin and Manfred E. Karobath, M.D. constitute a class with a term ending at the 2008 annual meeting.
  ...
  Dr. Caspritz has informed us that he will not stand for re-election at the annual meeting.As discussed below in "ELECTION OF DIRECTOR (Notice Item 1)," one board seat will be vacated when Dr. Caspritz's term on the Board expires at the annual meeting.

• 
  www.clavispharma.com/Company/Board+of+Directors/385.cms - [Cached Version]
  Published on: 12/24/2005    Last Visited: 11/3/2009  

  Gert Caspritz
  
  Gert Caspritz joined NeoMed Management as senior investment professional and partner in September 2008.
  
  From 1999 to 2008 he was an Investment Manager and General Partner at TVM Capital's life science practice in Boston. Prior to that he worked for 18 years at Hoechst AG and its various affiliates (now known as Sanofi-Aventis) in Frankfurt, Germany; Kansas City, KS and Bridgewater, NJ.
  
  His most recent position was Vice President of New Technologies Licensing in the Global Business Development Group, where he also oversaw investments in various life science venture capital funds. During his tenure at Hoechst he also served two years as the Assistant to the Head of Worldwide Research with broad responsibilities for budget, personnel and investments.
  
  Gert Caspritz received a PhD in Biology from the Johannes Gutenberg University in Mainz, Germany in 1981. During his tenure at TVM Capital, Gert Caspritz has been a board member of several life science companies, most recently Enanta Pharmaceuticals, Transave and Transmolecular.
  
  Gert Caspritz is a citizen of Germany.

Page:  1 2 3 4 5